Forbion Will Use New Fund To Rescue Struggling Biotechs
European VC Raises €1.35bn
The Netherlands and Germany-based VC firm wants to help out public and private companies who have undervalued late-stage assets and are struggling to raise new funds.
You may also be interested in...
Finance Watch: Venture Capital Funders Raise Billions For Biotech Investments
Private Company Edition: Forbion closed two funds totaling €1.35bn ($1.5bn) and Glide Healthcare raised €600m ($657.5m) for its latest fund, joining recent venture capital raises by Lux Capital and Wellington Management, but in the first quarter biopharma VC company financings fell dramatically.
Germany’s Complement Bets On Gene Therapy For Geographic Atrophy
US approval of Apellis's Syfovre has validated the complement approach for treating the advanced stage of age-related macular degeneration but a Munich-headquartered start-up believes its gene therapy will be a more potent and less burdensome alternative.
Novo Nordisk Broke UK Rules By ‘Disparaging’ Rival Eli Lilly
The Danish company has once again broken UK industry rules, this time by looking to get the upper hand on its GLP-1 receptor agonist market rival Eli Lilly.